Hong Yinghui, Ye Mingliang, Wang Junshi, Huang Lei
Department of Intensive Care, Peking University Shenzhen Hospital, Shenzhen, 518036, P. R. China.
Department of Emergency, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, 518003, P. R. China.
Stem Cell Rev Rep. 2025 Apr;21(3):767-778. doi: 10.1007/s12015-025-10852-5. Epub 2025 Feb 14.
Several studies have reported the effectiveness of stem cell-derived extracellular vesicles (SC-EVs) in disease treatment. However, the efficacy of SC-EVs for severe acute pancreatitis (SAP) remains uncertain. This systematic review aimed to analyze and evaluate the effect of SC-EVs in the treatment of SAP in animal models by summarizing data from published studies.
We searched Pubmed, Embase, and Web of Science databases to identify preclinical studies investigating the therapeutic effect of SC-EVs on SAP. The primary outcome was the histopathological scores of pancreatic tissues, including inflammation, edema, and necrosis. Other outcome measures included levels of amylase, IL-6, IL-10, and TNF-α. Eligible studies were selected based on the inclusion and exclusion criteria. SYRCLE checklist was adopted to assess the quality and bias risks of included studies. Mean differences and 95% confidence intervals were calculated using the inverse variance method with a random effects model. All statistical analyses were performed using RevMan 5.3 software.
A total of 8 studies including 126 animals were included. The results of meta-analysis revealed that SC-EVs treatment significantly reduced pancreatic histopathologic scores (total score: MD = -5.17, 95% CI: -5.79, -4.55; inflammation score: MD = -1.44, 95% CI: -1.70, -1.19; edema score: MD = -1.42, 95% CI: -1.75, -1.09; necrosis score: MD = -1.42, 95% CI: -1.80, -1.04), inhibited pro-inflammatory factor release (IL-6: SMD = -3.20, 95% CI: -4.51, -1.88; TNF-α SMD = -5.18, 95% CI: -6.96, -3.40), and enhancing the release of anti-inflammatory factors (IL-10 SMD = 4.15, 95% CI: 2.49, 5.81). Further subgroup analyses displayed SC-EVs treatment obviously attenuated animal pancreatic pathologic injury in traumatic pancreatitis and drug-induced acute pancreatitis, and the effect of SC-EVs to inhibit TNF-α secretion in the drug-induced SAP model was correlated with the dose of SC-EVs injection.
This meta-analysis displayed that SC-EVs were correlated with SAP injury alleviation and pancreas function reservation. Research into the treatment of SAP with SC-EVs is still in its early stage, necessitating further comprehensive investigations in the future to elucidate the therapeutic mechanisms of SC-EVs and their potential application in SAP.
多项研究报道了干细胞衍生的细胞外囊泡(SC-EVs)在疾病治疗中的有效性。然而,SC-EVs 治疗重症急性胰腺炎(SAP)的疗效仍不确定。本系统评价旨在通过总结已发表研究的数据,分析和评估 SC-EVs 在动物模型中治疗 SAP 的效果。
我们检索了 Pubmed、Embase 和 Web of Science 数据库,以确定研究 SC-EVs 对 SAP 治疗效果的临床前研究。主要结局是胰腺组织的组织病理学评分,包括炎症、水肿和坏死。其他结局指标包括淀粉酶、IL-6、IL-10 和 TNF-α 的水平。根据纳入和排除标准选择符合条件的研究。采用 SYRCLE 清单评估纳入研究的质量和偏倚风险。使用随机效应模型的逆方差法计算平均差异和 95%置信区间。所有统计分析均使用 RevMan 5.3 软件进行。
共纳入 8 项研究,涉及 126 只动物。荟萃分析结果显示,SC-EVs 治疗显著降低了胰腺组织病理学评分(总分:MD = -5.17,95%CI:-5.79,-4.55;炎症评分:MD = -1.44,95%CI:-1.70,-1.19;水肿评分:MD = -1.42,95%CI:-1.75,-1.09;坏死评分:MD = -1.42,95%CI:-1.80,-1.04),抑制促炎因子释放(IL-6:SMD = -3.20,95%CI:-4.51,-1.88;TNF-α SMD = -5.18,95%CI:-6.96,-3.40),并增强抗炎因子的释放(IL-10 SMD = 4.15,95%CI:2.49,5.81)。进一步的亚组分析显示,SC-EVs 治疗明显减轻了创伤性胰腺炎和药物性急性胰腺炎动物的胰腺病理损伤,且 SC-EVs 在药物性 SAP 模型中抑制 TNF-α 分泌的效果与 SC-EVs 注射剂量相关。
本荟萃分析表明,SC-EVs 与减轻 SAP 损伤和保留胰腺功能相关。用 SC-EVs 治疗 SAP 的研究仍处于早期阶段,未来需要进一步全面研究以阐明 SC-EVs 的治疗机制及其在 SAP 中的潜在应用。